Journal Article
. 2014 Oct; 33(8):916-22.
doi: 10.1200/JCO.2014.55.6894.

Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score

Ivana Sestak 1 Jack Cuzick 2 Mitch Dowsett 2 Elena Lopez-Knowles 2 Martin Filipits 2 Peter Dubsky 2 John Wayne Cowens 2 Sean Ferree 2 Carl Schaper 2 Christian Fesl 2 Michael Gnant 2 
Affiliations
  • PMID: 25332252
  •     61 citations

Abstract

Purpose: We have previously shown that the PAM50-based risk of recurrence (ROR) score is significantly correlated with distant recurrence in both the translational research cohort within the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial (TransATAC) and Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG 8) randomized trials. Here, we focus on the ROR score for predicting distant recurrence after 5 years of follow-up in a combined analysis of these two randomized trials.

Methods: Long-term follow-up data and tissue samples were obtained from 2,137 postmenopausal women with hormone receptor-positive early-stage breast cancer from the ABCSG 8 and TransATAC trials. We used Cox proportional hazard regression models to determine the prognostic value of ROR for distant recurrence beyond 5 years in the combined data set.

Results: A total of 2,137 women who did not have a recurrence 5 years after diagnosis were included in the combined analyses. The Clinical Treatment Score (CTS) was the strongest prognostic factor 5 years after diagnosis (univariable: likelihood ratio [LR] χ(2) = 94.12, bivariable: LR χ(2) = 61.43). The ROR score was significantly prognostic by itself in years 5 to 10. In the node-negative/human epidermal growth factor receptor 2-negative subgroup, more prognostic value for late distant recurrence was added by the ROR score compared with the CTS.

Conclusion: The ROR score added clinically meaningful prognostic information to the CTS in all patients and all subgroups in the late follow-up period. These results suggest that the ROR score may be helpful for separating patients into risk groups who could be spared or potentially benefit from extended hormonal therapy beyond 5 years of treatment.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.
Cornelia Liedtke, Marc Thill, +2 authors, AGO Breast Committee.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177261    Free PMC article.
[Molecular pathology for breast cancer: Importance of the gene expression profile].
C Denkert, B M Pfitzner, B I Heppner, M Dietel.
Pathologe, 2015 Apr 04; 36(2). PMID: 25836324
Review.
Markers for the identification of late breast cancer recurrence.
Ivana Sestak, Jack Cuzick.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25848913    Free PMC article.
Review.
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
Kathleen Van Asten, An Poppe, +4 authors, Patrick Neven.
Curr Treat Options Oncol, 2015 Jun 03; 16(7). PMID: 26031545
Review.
Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Marco Colleoni, Elisabetta Munzone.
Drugs, 2015 Jul 17; 75(12). PMID: 26177891
Review.
Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?
Wilbert Zwart, Huub Terra, Sabine C Linn, Sanne B Schagen.
Nat Rev Clin Oncol, 2015 Jul 22; 12(10). PMID: 26196252
Review.
Predicting benefit of endocrine therapy for early breast cancer.
Meredith M Regan.
Breast, 2015 Aug 10; 24 Suppl 2. PMID: 26255197    Free PMC article.
Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Tara Sanft, Bilge Aktas, +11 authors, Lajos Pusztai.
Breast Cancer Res Treat, 2015 Nov 19; 154(3). PMID: 26578401    Free PMC article.
Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.
Jill M Siegfried, Yan Lin, +7 authors, Laura P Stabile.
Neoplasia, 2015 Dec 19; 17(11). PMID: 26678909    Free PMC article.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives.
Meagan B Myers.
Pharmgenomics Pers Med, 2016 Feb 10; 9. PMID: 26858530    Free PMC article.
Review.
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
Norman Wolmark, Eleftherios P Mamounas, +6 authors, Soonmyung Paik.
J Clin Oncol, 2016 May 25; 34(20). PMID: 27217450    Free PMC article.
Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.
Eun-Shin Lee, Wonshik Han, +9 authors, Eun Sook Lee.
BMC Cancer, 2016 Jul 09; 16. PMID: 27388210    Free PMC article.
Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors.
Ivana Sestak, Mitch Dowsett, +2 authors, Jack Cuzick.
Breast Cancer Res Treat, 2016 Jul 23; 159(1). PMID: 27447876    Free PMC article.
Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.
Flora Stavridi, Konstantine T Kalogeras, +19 authors, George Fountzilas.
PLoS One, 2016 Oct 04; 11(10). PMID: 27695115    Free PMC article.
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Review.
Clinico-Pathologic Subtypes of Breast Cancer Primary Tumors Are Related to Prognosis after Recurrence
Cesar Sánchez, Mauricio Camus, +8 authors, Francisco Acevedo.
Asian Pac J Cancer Prev, 2017 Jan 27; 17(12). PMID: 28122438    Free PMC article.
Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?
Ann H Partridge, Lisa A Carey.
Clin Cancer Res, 2017 Jun 03; 23(11). PMID: 28572255    Free PMC article.
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.
Terri P McVeigh, Michael J Kerin.
Breast Cancer (Dove Med Press), 2017 Jun 16; 9. PMID: 28615971    Free PMC article.
Review.
Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy.
Ivana Sestak.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785181    Free PMC article.
Review.
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
Prema P Peethambaram, Tanya L Hoskin, +3 authors, Judy C Boughey.
NPJ Breast Cancer, 2017 Oct 27; 3. PMID: 29067357    Free PMC article.
Clinical utility of multigene profiling assays in early-stage breast cancer.
M C Chang, L H Souter, +6 authors, Molecular Oncology Advisory Committee.
Curr Oncol, 2017 Nov 02; 24(5). PMID: 29089811    Free PMC article.
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan, Richard Gray, +9 authors, EBCTCG.
N Engl J Med, 2017 Nov 09; 377(19). PMID: 29117498    Free PMC article.
Highly Cited.
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Hege O Ohnstad, Elin Borgen, +11 authors, Bjørn Naume.
Breast Cancer Res, 2017 Nov 16; 19(1). PMID: 29137653    Free PMC article.
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
M C U Cheang, J M Bliss, +13 authors, PathIES Sub-Committee.
Breast Cancer Res Treat, 2017 Nov 28; 168(1). PMID: 29177605    Free PMC article.
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
R Colomer, I Aranda-López, +7 authors, J Palacios-Calvo.
Clin Transl Oncol, 2017 Dec 24; 20(7). PMID: 29273958    Free PMC article.
Review.
Arachidonic Acid Metabolite as a Novel Therapeutic Target in Breast Cancer Metastasis.
Thaiz F Borin, Kartik Angara, +2 authors, Ali S Arbab.
Int J Mol Sci, 2018 Jan 03; 18(12). PMID: 29292756    Free PMC article.
Review.
Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?
I S Bhattacharya, A M Kirby, J M Bliss, C E Coles.
Clin Oncol (R Coll Radiol), 2018 Jan 15; 30(3). PMID: 29331262    Free PMC article.
Review.
Optimal duration of adjuvant endocrine therapy: how to apply the newest data.
Kerstin Wimmer, Stephanie Strobl, +5 authors, Michael Gnant.
Ther Adv Med Oncol, 2018 Jan 19; 9(11). PMID: 29344105    Free PMC article.
Review.
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ivana Sestak, Richard Buus, +9 authors, Mitch Dowsett.
JAMA Oncol, 2018 Feb 17; 4(4). PMID: 29450494    Free PMC article.
Highly Cited.
Challenges in using liquid biopsies for gene expression profiling.
Tania B Porras, Pushpinder Kaur, +2 authors, Julie E Lang.
Oncotarget, 2018 Feb 23; 9(6). PMID: 29467948    Free PMC article.
Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.
Irene E G van Hellemond, Sandra M E Geurts, Vivianne C G Tjan-Heijnen.
Curr Treat Options Oncol, 2018 Apr 29; 19(5). PMID: 29704066    Free PMC article.
Review.
Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.
S K L Chia.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910655    Free PMC article.
Review.
Genomic Testing in the Management of Early-Stage Breast Cancer.
Sima Ehsani, Kari Braun Wisinski.
J Clin Outcomes Manag, 2017 May 01; 24(5). PMID: 30158821    Free PMC article.
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Richard Buus, Belinda Yeo, +7 authors, Mitch Dowsett.
Breast Cancer Res, 2018 Sep 06; 20(1). PMID: 30180877    Free PMC article.
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Marie Alexandre, Aurélie Maran-Gonzalez, +6 authors, Séverine Guiu.
Cancer Manag Res, 2019 Dec 19; 11. PMID: 31849525    Free PMC article.
Review.
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence.
Fabio Conforti, Laura Pala, +12 authors, Aron Goldhirsch.
Breast Cancer Res, 2020 Jan 01; 21(1). PMID: 31888717    Free PMC article.
Development and verification of a nomogram for prediction of recurrence-free survival in clear cell renal cell carcinoma.
Yuanlei Chen, Shangjun Jiang, +7 authors, Gonghui Li.
J Cell Mol Med, 2019 Nov 30; 24(2). PMID: 31782902    Free PMC article.
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients.
Maj-Britt Jensen, Anne-Vibeke Lænkholm, +9 authors, Bent Ejlertsen.
NPJ Breast Cancer, 2020 Mar 07; 6. PMID: 32140564    Free PMC article.
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Joseph Sparano, Anne O'Neill, +5 authors, Kathy D Miller.
JAMA Oncol, 2018 Jul 29; 4(12). PMID: 30054636    Free PMC article.
Highly Cited.
Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?
Kevin Kalinsky, Ruth M O'Regan.
Cancer, 2018 Nov 06; 125(2). PMID: 30387877    Free PMC article.
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Thomas Ruhstaller, Anita Giobbie-Hurder, +27 authors, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group.
J Clin Oncol, 2018 Nov 27; 37(2). PMID: 30475668    Free PMC article.
Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage.
Jieun Koh, Min Jung Kim.
Korean J Radiol, 2019 Jan 11; 20(1). PMID: 30627023    Free PMC article.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
Review.
DEAD-box RNA Helicase 39 Promotes Invasiveness and Chemoresistance of ER-positive Breast Cancer.
Xiudi Wang, Peipei Li, +4 authors, Jiajin Lin.
J Cancer, 2020 Mar 21; 11(7). PMID: 32194796    Free PMC article.
Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value.
Changjun Wang, Chang Chen, +10 authors, Qiang Sun.
Sci Rep, 2020 Mar 15; 10(1). PMID: 32170181    Free PMC article.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
Ryan J O Dowling, Kevin Kalinsky, +29 authors, Pamela J Goodwin.
JNCI Cancer Spectr, 2020 Apr 28; 3(4). PMID: 32337479    Free PMC article.
Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer.
Gagan Gupta, Caroline Dasom Lee, +10 authors, Amy H Tang.
Ann Breast Cancer Ther, 2020 Jun 17; 4(1). PMID: 32542231    Free PMC article.
Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.
Aurelia Noske, Sophie-Isabelle Anders, +6 authors, Evelyn Klein.
Breast, 2019 Dec 02; 49. PMID: 31786414    Free PMC article.
An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer.
Yi-Xing Wang, Yuan-Yuan Wang, +9 authors, Ju-Lun Yang.
Breast, 2020 Jan 09; 49. PMID: 31911370    Free PMC article.
Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.
Garazi Serna, Sara Simonetti, +10 authors, Paolo Nuciforo.
Breast, 2020 Jul 25; 53. PMID: 32707454    Free PMC article.
Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication.
Takayuki Ueno, Shigehira Saji, +11 authors, Masakazu Toi.
ESMO Open, 2019 Apr 10; 4(1). PMID: 30962956    Free PMC article.
Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.
José P Leone, Bernardo A Leone, +7 authors, Nancy U Lin.
Breast Cancer Res Treat, 2021 Feb 17; 187(3). PMID: 33590387
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
Paolo Giorgi Rossi, Annette Lebeau, +13 authors, ECIBC Contributor Group.
Br J Cancer, 2021 Feb 19; 124(9). PMID: 33597715    Free PMC article.
Review.
Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Maroun Bou Zerdan, Maryam Ibrahim, +2 authors, Hazem I Assi.
Front Oncol, 2021 Mar 06; 10. PMID: 33665165    Free PMC article.
Review.
Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2- Early Breast Cancer.
Mi Jeong Kwon, Jai Min Ryu, +12 authors, Jeong Eon Lee.
Front Oncol, 2021 Mar 13; 11. PMID: 33708625    Free PMC article.
Random Forest Modelling of High-Dimensional Mixed-Type Data for Breast Cancer Classification.
Jelmar Quist, Lawson Taylor, Johan Staaf, Anita Grigoriadis.
Cancers (Basel), 2021 Mar 07; 13(5). PMID: 33673506    Free PMC article.
Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.
Juliet Richman, Alistair Ring, Mitch Dowsett, Ivana Sestak.
Breast Cancer Res Treat, 2020 Nov 23; 186(1). PMID: 33222093    Free PMC article.
Factors associated with late risks of breast cancer-specific mortality in the SEER registry.
José P Leone, Carlos T Vallejo, +8 authors, Nancy U Lin.
Breast Cancer Res Treat, 2021 Apr 25; 189(1). PMID: 33893907    Free PMC article.